Acumen Pharmaceuticals, Inc.
ABOS
$2.41
$0.010.42%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 4.89% | -284.65% | -19.37% | 90.06% | -92.11% |
| Gross Profit | -4.89% | 284.65% | 19.37% | -90.06% | 92.11% |
| SG&A Expenses | -8.60% | -7.06% | -9.43% | -4.60% | -4.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -30.36% | -36.36% | -17.83% | 71.24% | 70.87% |
| Operating Income | 30.36% | 36.36% | 17.83% | -71.24% | -70.87% |
| Income Before Tax | 27.99% | 32.34% | 11.13% | -99.40% | -93.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 27.99% | 32.34% | 11.13% | -99.40% | -93.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 27.99% | 32.34% | 11.13% | -99.40% | -93.61% |
| EBIT | 30.36% | 36.36% | 17.83% | -71.24% | -70.87% |
| EBITDA | 30.37% | 36.37% | 17.83% | -71.29% | -70.94% |
| EPS Basic | 31.06% | 32.89% | 11.85% | -97.78% | -91.31% |
| Normalized Basic EPS | 31.07% | 32.88% | 11.85% | -97.80% | -91.38% |
| EPS Diluted | 31.06% | 32.89% | 11.85% | -97.78% | -91.31% |
| Normalized Diluted EPS | 31.07% | 32.88% | 11.85% | -97.80% | -91.38% |
| Average Basic Shares Outstanding | 4.45% | 0.82% | 0.82% | 0.82% | 1.19% |
| Average Diluted Shares Outstanding | 4.45% | 0.82% | 0.82% | 0.82% | 1.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |